Biodesix Announces Second Quarter 2022 Results and Highlights

Second quarter 2022 core Lung Diagnostic revenue of $7.3 million increased 52% over the comparable period in 2021; Received Medicare coverage for the Nodify CDT® Lung Nodule Test; Announced strategic arrangements during the quarter (Royal Philips, Memorial Sloan Kettering Cancer Center and Bio-Rad); Reaffirm 2022 revenue outlook of between $37.5 million and $39.5 million; Conference … [Read more…]

NanoString to Webcast Presentations from Two Upcoming Healthcare Conferences

SEATTLE–(BUSINESS WIRE)–#earnings–NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast presentations from two upcoming healthcare conferences. 42nd Annual Canaccord Global Growth Conference Wednesday, August 10th Brad Gray, NanoString’s chief executive officer, will participate in a spatial biology panel titled, … [Read more…]

Pediatrix Medical Group Reports Second Quarter Results

FORT LAUDERDALE, Fla.–(BUSINESS WIRE)–$MD–Pediatrix Medical Group, Inc. (NYSE: MD), the nation’s leading provider of highly specialized health care for women, children and babies, today reported earnings from continuing operations of $0.36 per share for the three months ended June 30, 2022. On a non-GAAP basis, Pediatrix reported Adjusted EPS from continuing operations of $0.47. For … [Read more…]

Aurinia Reports Second Quarter and Six Months 2022 Financial and Operational Results

Net revenue increased to $28.2 million for Q2 2022; Maintains net revenue guidance range of $115-$135 million from sales of LUPKYNIS® (voclosporin) for 2022 Continued increases in LUPKYNIS Patients on Treatment; Steady Conversion Rates and Payor Coverage EMA review of LUPKYNIS remains on track with decision expected by the end of Q3 2022 $391.7 million … [Read more…]

North America Idiopathic Pulmonary Fibrosis Market Report 2022: Growth of 5.6% Expected Annually, Driven by Key Players GNI Group, AstraZeneca & Others Shionogi & Co, – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “North America Idiopathic Pulmonary Fibrosis Market Size, Share & Industry Trends Analysis Report By Drug Type, By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Providers, By Country and Growth Forecast, 2021-2027” report has been added to ResearchAndMarkets.com’s offering. The North America Idiopathic Pulmonary Fibrosis Market is expected to witness market growth of … [Read more…]

AIBODY Partners with German Heart Centre Berlin to Revolutionize Diagnosis and Treatment of Congenital Heart Disease

LONDON–(BUSINESS WIRE)–AIBODY, the world’s first Physiology-as-a-Service platform, announced today that it has signed a collaboration agreement with the German Heart Centre Berlin (DHZB), a leading medical research institute specializing in cardiovascular disease. This agreement focuses on the development of a suite of innovative solutions that will facilitate the diagnosis and treatment of congenital heart disease. … [Read more…]

European Commission Approves IMBRUVICA® (ibrutinib) in a Fixed-Duration Combination Regimen for Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

Approval marks the first all-oral, once-daily, fixed-duration Bruton’s tyrosine kinase (BTK) inhibitor-based regimen for first-line treatment of CLL BEERSE, Belgium–(BUSINESS WIRE)–The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission granted marketing authorisation for the expanded use of IMBRUVICA® (ibrutinib) in an all-oral, fixed-duration (FD) treatment combination with venetoclax (I+V) for … [Read more…]

GenomOncology and Congenica Announce Collaborative Development of Novel Precision Oncology Solution

CAMBRIDGE, England–(BUSINESS WIRE)–#lifechanginganswers–Congenica, a UK-based digital health company that enables the rapid analysis and interpretation of genomic data, has selected the GenomOncology Precision Oncology Platform for the development of a novel ground-breaking CE-IVD Precision Oncology Solution. Driven by the increasing adoption of cancer genomics and the growing need to individualize therapeutic recommendations, Congenica is developing … [Read more…]

PureTech Health: Notice of Half-Yearly Results

BOSTON–(BUSINESS WIRE)–PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”) plans to announce its half-yearly results for the six months ended June 30, 2022, on Thursday, August 25, 2022. A presentation and conference call for analysts and shareholders will take place at 9:00am EDT / 2:00pm BST on the day of publication, and … [Read more…]

Revolutionizing Healthcare Testing: 1health Unveils Next Generation Diagnostic Platform that Enables Precision Medicine at Scale

Labs can now launch next-gen testing in days versus months and improve patient experience and outcomes SAN FRANCISCO–(BUSINESS WIRE)–1health.io Inc. (“1health”), an industry-leading healthcare tech company that empowers laboratories to make diagnostic testing accessible and affordable at scale, announces the launch of its Next Generation Diagnostic Platform. With 1health’s innovative platform, laboratories can expand market … [Read more…]